Posted on

M2Bio Sciences Attending Master Investor Show in London, UK

M2Bio Sciences Attending Master Investor Show in London, UK

CAPE TOWN, SA / ACCESSWIRE / March 16, 2022 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:

M2Bio Sciences is pleased to announce that CEO Jeff Robinson and Chief Medical Officer Dr. Anna Morera Leralta will be attending the Master Investor Show in London, UK at the Business Design Centre, Saturday, 19 March 2022.

The event will host approximately 5000 attendees throughout the day and feature investment categories ranging from biotechnology, longevity, regenerative medicine, AI, blockchain, agronomics and many more. The show will also feature the latest insights from well-known personalities in the UK investment industry. Jeff Robinson and Dr. Anna Morera Leralta will meet with retail and institutional investors, academics and speakers Jim Mellon, with whom Dr. Anna Morera Leralta completed an internship in London in 2016 and Dr. Greg Bailey of Juvenescence.

“Both Dr. Anna and I are very excited to attend our fifth Master Investor Show. Expanding our knowledge base and networking is so very important, not to mention being able to attend an event in person finally! We would like to extend an invitation to all our friends in London to join us and meet up for a coffee.” said Jeff Robinson – CEO

Jeff is currently in London (March 16 – March 22) and can be reached at jeff@m2bio.co

Master Investor annually host their flagship event, ‘The Master Investor Show’, introducing private investors to a day filled with networking opportunities, presentations and professional guidance from the leading companies and best experts within the financial and investment sectors. Covering various industries, this event caters to a wide audience and is definitely not one to be missed.

Master Investor Show also provides access to the broadest spectrum of investment opportunities to be found; from Trusts and Funds to Small Cap Companies and beyond to Start-Ups in the early stages of fund raising. Meet and hear from experts about what they are investing in and why.

You can get tickets here or if you can’t make it it can be viewed via livestream here.

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Publicly traded company (OTC Pink: WUHN)
Visit Website
Contact via E-mail
Follow us on Twitter
Follow us on Facebook
Follow us on YouTube
Follow us on Instagram

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.

View source version on accesswire.com:
https://www.accesswire.com/693318/M2Bio-Sciences-Attending-Master-Investor-Show-in-London-UK

Posted on

M2Bio Labs Offers Ketamine IV & Personalized Supercharged Vitamin IV Drip

M2Bio Labs Offers Ketamine IV & Personalized Supercharged Vitamin IV Drip

CAPE TOWN, SA / ACCESSWIRE / March 10, 2022 / WUHAN GENERAL GROUP, INC. (WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:

M2Bio Sciences is pleased to announce the rollout of its on-site Ketamine and Supercharged Vitamin IV Therapy at the M2Bio Labs in Hout Bay, Cape Town.

Drip therapy has long been used in hospitals and clinics to administer medicine for the main benefit of 100% bioavailability. This means that all the medicine, nutrients, or minerals are absorbed by the body because it’s being fed directly into the bloodstream.

Supercharged Vitamin and CBD IV Drip

The customized intravenous vitamin drips will offer various therapies and vitamin cocktails designed to target very specific health needs. They will support your physical and mental well-being, detox the body, boost the immune system, assist with recovery from strenuous training sessions, nourish and repair hair, skin, and nails, all to get your mind and body to peak performance.

The drips will offer the following benefits to clients:

  • Instantly increase the body’s antioxidant, mineral, and nutrient count.
  • Oxygenate the blood, flush out toxins, help with lymph production.
  • Increase energy, lower body temperature, decrease constipation.
  • Reduce swelling and help fight off infections.
  • Improve sleep quality.
  • Increased metabolism and potential weight loss.
  • Aids fertility and libido.
  • Improve concentration and mental clarity.

There will also be the option of CBD (cannabidiol) vitamin drip as part of the product offering. The IV drip method is the fastest and most effective way to get CBD into the patients’ endocannabinoid system and is far more effective than traditional oral, inhaled, transdermal, or sublingual delivery methods.

Ketamine IV Infusions and Assisted Psychotherapy (KAP)

The labs will also feature a Ketamine Infusion Facility and Ketamine Assisted Psychotherapy for treating patients with mental illness, mood disorders, and chronic pain, these include:

  • Treatment Resistant Depression
  • Suicidality
  • Eating Disorders
  • Bipolar Disorder
  • Anxiety and Panic Attacks
  • PTSD
  • OCD
  • Postpartum Depression
  • Alcoholism and Addiction
  • Neuralgia
  • Neuropathic pain associated with Diabetes, Demyelination, Cancer, or HIV.
  • Complex Regional Pain Syndrome (CRPS).

Pain associated with Multiple Sclerosis or Parkinson’s disease.

  • Migraine headaches and Fibromyalgia.

Patients will be treated in sessions typically lasting 2-3 hours, this process includes the ketamine administration by fully qualified members of the medical team in a comfortable environment. The medical staff will consist of doctors, nurses, psychologists, and psychiatrists. Patients will be fully guided through the entire process.

“We are very excited about the addition of the IV Vitamin and Ketamine divisions. This will add great depth and value to our current offerings at M2Bio Labs. Our clients and patients will have the opportunity to experience various mental and physical wellness therapies all in one convenient location. We will change many lives for the better at the labs.” said Jeff Robinson, Wuhan General Inc, CEO.

About Ketamine and Ketamine Assisted Psychotherapy

Ketamine is an FDA-approved anesthetic that’s been widely used around the world for more than five decades. It’s also a medication with fast-acting antidepressant properties.

While ketamine isn’t considered a first-line therapy for chronic pain, depression, or any other mental health disorder, it can be used off-label to treat severe cases of depression, anxiety, and PTSD that haven’t responded to conventional medications or therapies.

When ketamine is administered through a slow, constant intravenous (IV) drip, it has calming and therapeutic effects on the regions of your brain that control mood and behavior.

KAP is an integrative psychotherapeutic modality.

By using this therapy during a non-ordinary state of consciousness, the therapist is able to support the patient in their exploration of particular suppressed material with less resistance. The client is encouraged to share as much, or as little as they wish during the administration session. Once the client has fully reconnected with their environment, an integration session is used to explore and make meaning of the material, together with the therapist. There is a strong emphasis on mindfulness, the re-examination of one’s core values, and how to apply value-driven actions into the client’s current life circumstances.

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Publicly traded company (OTC Pink:WUHN)
Website: www.m2bio.co
E-mail: info@m2bio.co

Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio
Follow us on YouTube: https://www.youtube.com/channel/M2BioSciences
Follow us on Instagram: https://www.instagram.com/m2bio.sciences/

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.

View source version on accesswire.com:
https://www.accesswire.com/692499/M2Bio-Labs-Offers-Ketamine-IV-Personalized-Supercharged-Vitamin-IV-Drip

Posted on

M2Bio Rolls Out Sustainable Packaging for Liviana

M2Bio Rolls Out Sustainable Packaging for Liviana

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / December 31, 2021 /WUHAN GENERAL GROUP, INC. (WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:

M2Bio Sciences is pleased to announce the rollout of its sustainable packaging solution – Hempcelium™ to be piloted and implemented by it’s Liviana™ Extra Virgin Olive Oil brand. The state-of-the-art sustainable packaging is customized to fit its Extra Virgin Olive Oil glass bottles. The solution is a Hempcelium™ transport packaging foam made from hemp agri-waste and mushroom mycelium.

Hempcelium™ is a unique composite that outperforms most other sustainable alternatives currently available. The Hempcelium™ packaging structure is completely organic and can be grown into almost any shape, making it as versatile as styrofoam or polystyrene, less the damage and pollution that comes from using a conventional synthetic material. Because Hempcelium™ is grown and not produced with chemical compounds that need large amounts of energy to synthesize, the carbon footprint is very low, and there are zero industrial chemical byproducts emitted that are harmful to the natural environment, our water, ecosystems, food-chains and human health.

The unique Hempcelium™ composite has been developed in-house by its team of engineers at the M2Bio Sustainability Labs during 2021 and is ready for the South African market. The company is in the process of obtaining all necessary legal and copyrights pertaining to the trademark name Hempcelium™. M2Bio Sciences’ Intellectual Property and Trademark legal team expects the process to be successfully concluded in Q1 2022.

“When you get the product with the packaging you are able to crumble up the Hempcelium™ foam into your garden bed or soil to decompose and support the health of your vegetation. Hempcelium serves an important function in the decomposition of organic matter in the soil. Research has demonstrated that it acts as a filter, removing groundwater contaminants and pollutants. It has shown potential to remove industrial toxins from the soil, which includes pesticides, chlorine, dioxin (a highly toxic environmental pollutant) as well as PCBs (highly toxic industrial compounds). In the garden, Hempcelium helps to increase nutrients available to plants, improve water efficiency, reduce erosion by acting as a cellular net, and promote root growth by adding oxygen to the soil and releasing nitrogen, phosphate, and other micronutrients. Simply put, it has a ton of benefits.” – Jeff Robinson, CEO of M2Bio Sciences.

Hempcelium™ packaging solution for single & multiple bottles

Mr. Robinson continues: “We and our customers are increasingly aware of the importance of sustainable and biodegradable materials. As a company, it has been at the core of product development to ensure all of our materials and ingredients adhere to such standards. We are now proud to take it to the next level, and deliver our own innovative solution to our customers, by introducing our sustainable packaging foam to one of our brands, Liviana.”

In addition, M2Bio is developing multiple packaging solutions for its other product lines and brands – Medspresso™ and Dr. AnnaRx™, which will be ready during the course of 2022.

“This will be a watershed moment for the sustainability drive globally. M2Bio will licence the technology to the rest of the world, with the goal of reducing and replacing synthetics entirely. We are super stoked for what comes next” – Jeff Robinson, CEO of M2Bio Sciences.

Hempcelium™ packaging solution for Dr. AnnaRx products

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Publicly traded company (OTC Pink: WUHN)

Website: www.m2bio.co

E-mail: info@m2bio.co

Follow us on Twitter: https://twitter.com/m2bio

Follow us on Facebook: http://www.facebook.com/m2bio

Follow us on YouTube: https://www.youtube.com/channel/M2BioSciences

Follow us on Instagram: https://www.instagram.com/m2bio.sciences/

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.

View source version on accesswire.com:
https://www.accesswire.com/680355/M2Bio-Rolls-Out-Sustainable-Packaging-for-Liviana

Posted on

M2Bio Director of Health and Fitness Rob Simbowe Visits Zambia and Hosts Vulnerable Youth Symposium

M2Bio Director of Health and Fitness Rob Simbowe Visits Zambia and Hosts Vulnerable Youth Symposium

CAPE TOWN, SA / ACCESSWIRE / December 16, 2021 / WUHAN GENERAL GROUP, INC. (WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update:

M2Bio Sciences is pleased to announce its Director of Health and Fitness, Brand Ambassador, and MMA Champion Rob Simbowe (AKA Black Tiger) visited Zambia and hosted the Vulnerable Youth Program and Symposium for underprivileged children. In addition, Rob visited the Fountain of Hope Orphanage, where he grew up, to speak with the kids, offer support, and donate much-needed dry goods in a country that is ravished with poverty, inadequate sanitation, poor health facilities, and widespread diseases like HIV/AIDS. Despite all the economic hardships and obstacles, the orphanage provided Rob with food, shelter, and love when he needed it most.

The first MMA Zambia Symposium took place in Lusaka November 25-28th and was also attended by the current MMA Bellator Featherweight champion, Cris Cyborg Justino.

“The sport of Mixed Martial Arts is a powerful tool for changing lives and for positive social change. We have been blessed to witness firsthand how Cris Cyborg Justino and Rob Simbowe use the sport to uplift those around them and empower young athletes, it’s truly inspiring.”
– Ben Bush, MMA Zambia President.

In his role as Director of Health and Fitness, Rob works with the M2Bio Sciences’ product development team to create new lines of sports nutrition supplements, topical ointments, muscle rubs, and foodicine product lines designed for athletes and optimum performance. His knowledge of the sports nutrition market and his network internationally are invaluable to growing the M2Bio consumer-facing brands – Medspresso™ and Dr. AnnaRx™. Rob Simbowe is also involved in the promotion of the new products as the face of sports nutrition for M2Bio Sciences’ current and new product categories to be launched in 2022.

The Rob Simbowe Story

Born August 14, 1987, Simbowe, an only child, lost his parents in 2000. As an orphan, he lived and slept on the streets of Lusaka, Zambia. During this time he met other street kids who were in the same dire situation and had no place to call home.

“I managed to survive the many cold nights of living with no food, no shelter, and sleeping under bridges to become a professional MMA champion fighter.” – Rob Simbowe.

Simbowe lived on the street until he was taken in by the Fountain of Hope Orphanage located in Lusaka’s Kamwala Township where he was presented with a chance to go to school, which back then, he couldn’t use because he was too used to life on the street.

“Life was hard. I remember what I went through and not having parents, not having anyone support me. I lived at Fountain of Hope in 2001. I was among the first street kids at the orphanage. There were guys who were doing drama. They were not like me because they were patient enough to sit and study, but for me, I couldn’t see that. All I wanted was to work and hustle so I never grabbed the opportunity to study.” – Rob Simbowe.

After realizing that education can make living on the streets a temporary experience instead of a lifelong sentence, Simbowe decided to take up another form of education which was to join the sport of boxing. After relocating to South Africa, Simbowe spent his early years selling sunglasses and African memorabilia to tourists at Cape Town’s beachfront before being spotted by international promoters who helped him become Zambia’s first professional MMA fighter.

“When the opportunity came for me to go to South Africa I just told myself that I will have to give my best and try by all means to survive. I told myself that I’m going to work hard and not take what doesn’t belong to me. I went with strong principles and because of my hard work and good deeds, I’m now reaping good things. If you do good to people, you reap good things.” – Rob Simbowe.

Now being coached by Scorant Aya and Sithembiso Hadebe of Untouchable Boxing, Simbowe’s ambition is to become the best fighter he can be and help make a difference in young people’s lives by offering the youth an opportunity and guidance to a healthy path towards a successful life.

Back to His Roots

Coming back to Zambia after so many years of being in South Africa and fighting professional MMA fights, he was compelled to go back to his orphanage, and home of his youth, to encourage the children to study hard, strive to be better, and excel.

“Regardless of who you are, let’s lead a life that will inspire others. Let’s make this world a better place for all of us to live in. It is important to leave a legacy that people can look up to. My journey has been amazing and I have met a lot of people who have helped me. To help me, you don’t need to give me money. To help me you don’t need to give me food. But that piece of advice, that piece of encouragement that can make me a better person.” – Rob Simbowe.

Simbowe’s gesture didn’t go unnoticed as MMA Zambia president Benjamin Bush hailed the athlete for his efforts to make the world a better place by inspiring the vulnerable kids.

“I was moved to tears when Rob was explaining his life story to the girls in the dormitory – I think they must have been between the ages of 6-14, talking to them about tips for life and how to get ahead. It was so moving. It was really something special,”
– Ben Bush, MMA Zambia President.

Bush said Simbowe and current Bellator MMA featherweight champion Cris Cyborg Justino played a key role in encouraging Zambian athletes during the first-ever MMA Zambia Symposium.

“The event was a massive success… without Rob, Cyborg, IMMAF and MMASA (Mixed Martial Arts South Africa), and M2Bio Sciences we would be nowhere… we can’t thank them enough. Our mission is all about using the sport for positive social change, creating role models, and creating a platform for athletes to achieve their dreams.” – Ben Bush, MMA Zambia President.

After going through so many challenges as an orphan and former street kid, it is gratifying to see Simbowe excel as an MMA fighter and become an exemplary role model like the greatest UFC champions Israel Adesanya and Kamaru Usman.

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Publicly traded company (OTC Pink:WUHN)

Website: www.m2bio.co

E-mail:info@m2bio.co

Follow us on Twitter: https://twitter.com/m2bio
Follow us on Facebook: http://www.facebook.com/m2bio
Follow us on Instagram: https://www.instagram.com/m2bio.sciences

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.

View source version on accesswire.com:
https://www.accesswire.com/678100/M2Bio-Director-of-Health-and-Fitness-Rob-Simbowe-Visits-Zambia-and-Hosts-Vulnerable-Youth-Symposium